Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation

奥西默替尼 T790米 间隙 医学 抗性突变 肺癌 内科学 突变 表皮生长因子受体 肿瘤科 酪氨酸激酶抑制剂 癌症 生物 埃罗替尼 泌尿科 遗传学 聚合酶链反应 基因 吉非替尼 逆转录酶
作者
Kana Watanabe,Ryota Saito,Eisaku Miyauchi,Hiromi Nagashima,Atsushi Nakamura,Shunichi Sugawara,Nobuyuki Tanaka,Hiroshi Terasaki,Tatsuro Fukuhara,Makoto Maemondo
出处
期刊:Cancers [Multidisciplinary Digital Publishing Institute]
卷期号:15 (17): 4231-4231 被引量:8
标识
DOI:10.3390/cancers15174231
摘要

BACKGROUND: Osimertinib was first approved for the treatment of non-small cell lung cancer (NSCLC) in patients who have developed the epidermal growth factor receptor (EGFR) T790M mutation after treatment with EGFR tyrosine kinase inhibitors (TKIs). We routinely evaluated the plasma of NSCLC patients with the T790M mutation to more rapidly detect an increase in disease activity and resistance to treatment. METHODS: Eligible patients received osimertinib after resistance to the first- or second-generation of EGFR-TKIs in NSCLC harboring T790M mutation detectable in tumor tissue or plasma. Plasma samples were collected every 8 weeks during osimertinib treatment. The plasma analysis was performed using an improved PNA-LNA PCR clamp method. We tested samples for a resistance mechanism, including EGFR-activating, T790M, and C797S mutations, and assessed the association between the mutations and osimertinib treatment. RESULTS: Of the 60 patients enrolled in the study, 58 were eligible for this analysis. In plasma collected before osimertinib treatment, activating mutations were detected in 47 of 58 patients (81.0%) and T790M was detected in 44 patients (75.9%). Activating mutations were cleared in 60.9% (28/46) and T790M was cleared in 93.0% (40/43). Of these, 71.4% (20/28) of activating mutations and 87.5% (35/40) of T790M mutation were cleared within 8 weeks of treatment. The total response rate (RR) was 53.4% (31/58). The median duration of treatment was 259 days, with a trend toward longer treatment duration in patients who experienced the clearance of activating mutations with osimertinib. At the time of disease progression during osimertinib treatment, C797S was detected in 3 of 37 patients (8.1%). CONCLUSION: Plasma EGFR mutation analysis was effective in predicting the effect of osimertinib treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小蘑菇的应助被劳小呆采纳,获得10
1秒前
ajing发布了新的文献求助20
2秒前
2秒前
3秒前
科研通AI6.2的应助被XZM采纳,获得10
3秒前
3秒前
sing完成签到 ,获得积分10
4秒前
4秒前
Mortal完成签到 ,获得积分10
5秒前
5秒前
纯真正豪发布了新的文献求助10
7秒前
酷波er的应助被JXY189采纳,获得10
7秒前
7秒前
香蕉觅云的应助被长庚采纳,获得10
7秒前
研友_ngqgY8完成签到,获得积分10
8秒前
9秒前
初(*^▽^*)心的应助被李宏梅采纳,获得10
10秒前
章鱼发布了新的文献求助10
11秒前
12秒前
Steven发布了新的文献求助30
13秒前
14秒前
啊呜完成签到,获得积分10
14秒前
可靠的马丁完成签到,获得积分10
15秒前
Maestro_S的应助被沈恺恺采纳,获得10
16秒前
16秒前
16秒前
ingst完成签到 ,获得积分10
17秒前
大佬发布了新的文献求助10
18秒前
万能图书馆的应助被FZ采纳,获得10
19秒前
AAA袁氏茶馆完成签到,获得积分10
19秒前
无花果的应助被刘白采纳,获得10
19秒前
水煮电吹风的应助被LL采纳,获得10
19秒前
裴腾骏完成签到,获得积分10
19秒前
20秒前
科研通AI6.2的应助被zo采纳,获得10
21秒前
21秒前
浮云客发布了新的文献求助10
25秒前
25秒前
ChoHing发布了新的文献求助10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500